Press Releases

Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales

May 15, 2023

Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference

May 11, 2023

Poxel Announces Availability of the 2022 Universal Registration Document and Provides Update on Accounts Settlement

May 3, 2023

Poxel Announces Multiple TWYMEEG® (Imeglimin) Abstracts Accepted for Oral Presentation

Apr 20, 2023

Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update

Mar 23, 2023

Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility

Mar 23, 2023

Poxel will Report its 2022 Full Year Results on March 23, 2023

Mar 22, 2023

Poxel to Report its 2022 Full Year Results by the End of March 2023

Mar 22, 2023

Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event

Mar 15, 2023

Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology

Mar 7, 2023